Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

Abstract Background Self-administered subcutaneous immunoglobulin G (SCIg) reduces nursing time and eliminates the need for treatment at ambulatory care clinics, as compared with clinic-based intravenously administered IgG (IVIg), and are therapeutically equivalent. Estimating the economic impact of...

Full description

Bibliographic Details
Main Authors:	Bruce Ritchie, Karen J. B. Martins, Dat T. Tran, Heather Blain, Lawrence Richer, Scott W. Klarenbach
Format:	Article
Language:	English
Published:	BMC 2022-11-01
Series:	Allergy, Asthma & Clinical Immunology
Subjects:	Immunoglobulin G Subcutaneous Intravenous Home-based administration Clinic-based administration Administrative data
Online Access:	https://doi.org/10.1186/s13223-022-00735-6

Similar Items

Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
by: Laimas Jonaitis, et al.
Published: (2021-12-01)

Predicting factors for the pattern of intravenous immunoglobulin utilization in a middle eastern university hospital
by: Zeinab Fakhari, et al.
Published: (2018-01-01)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
by: Philipp Scheuerlein, et al.
Published: (2018-07-01)

Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
by: Mona Al-Ahmad, et al.
Published: (2017-01-01)

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
by: Hsuan-Ping Chang, et al.
Published: (2023-04-01)

Continuous Intravenous versus Subcutaneous Administration of Insulin for Glycemic Variability in Acute Ischemic Stroke
by: Du LZ, et al.
Published: (2022-07-01)

Evaluation of rational prescription pattern of intravenous immunoglobulin (IVIG) based on FDA-approved indications among teaching hospitals in Birjand
by: Abolfazl Abbaszadeh, et al.
Published: (2022-04-01)

Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma
by: J. Fréderique de Graaf, et al.
Published: (2022-07-01)

Continuous Intravenous versus Subcutaneous Administration of Insulin for Glycemic Variability in Acute Ischemic Stroke [Corrigendum]
by: Du LZ, et al.
Published: (2022-08-01)

Life in public administration : who administers/ how, where and what does one administer/ how one learn to administer /
by: Klinkers, Leo
Published: (1985)

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis
by: Maria Dimou, et al.
Published: (2023-09-01)

Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review
by: Paolo Manganotti, et al.
Published: (2023-04-01)

Subcutaneous Biopharmaceutics: Building tools for a flexible future
by: Kate Louise Harris, et al.
Published: (2023-12-01)

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
by: Andrea Visentin, et al.
Published: (2022-12-01)

Assessing efficacy and safety of buccally inoculated midazolam and intravenously administered diazepam for relieving pediatric primary generalized epileptic seizures
by: A. G. Prityko, et al.
Published: (2021-07-01)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
by: Kristin Epland, et al.
Published: (2022-09-01)

Determination of adherence to labeled recommendations of intravenous antibiotics administration among health care providers: a cross-sectional study
by: Emad Elshebiny, et al.
Published: (2020-01-01)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
by: Dario Cocito, et al.
Published: (2023-11-01)

Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection
by: Sylvain Goutelle, et al.
Published: (2021-03-01)

Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis
by: Zbigniew Żuber, et al.
Published: (2016-03-01)

Cost-minimization analysis of oral and intravenous administration of linezolid in a public hospital in southern Brazil
by: Érika Taguti, et al.
Published: (2015-10-01)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
by: Jean Darloy, et al.
Published: (2019-01-01)

Intravenous Immunoglobulin Therapy in Myocarditis
by: Amir Hossein Mansourabadi, et al.
Published: (2020-08-01)

Case report: A case of severe retropharyngeal edema after COVID-19 successfully treated with intravenous immunoglobulin
by: Takanori Suzuki, et al.
Published: (2023-07-01)

Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks
by: Jonathan A. Bernstein, et al.
Published: (2019-03-01)

Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients
by: Cherie Severson
Published: (2015-07-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
by: Iannone F, et al.
Published: (2022-06-01)

Elemental mercury poisoning caused by subcutaneous and intravenous injection: An unusual self-injury
by: Jaywant Wale, et al.
Published: (2010-04-01)

Elemental mercury poisoning caused by subcutaneous and intravenous injection: An unusual self-injury
by: Wale Jaywant, et al.
Published: (2010-01-01)

INTRAVENOUS IMMUNOGLOBULIN THERAPY IN MEDICAL PRAXIS
by: Lidija Kareva
Published: (2016-12-01)

The Subcutaneous Administration of Beta-Lactams: A Case Report and Literary Review—To Do Small Things in a Great Way
by: Gabriele Maria Leanza, et al.
Published: (2024-01-01)

Hemolytic anemia following intravenous immunoglobulins in children with PIMS-TS: Two case reports
by: E. Sedlin, et al.
Published: (2023-04-01)

Intravenous Immunoglobulin and its Complications
by: I Mohammadzadeh
Published: (2011-05-01)

Successful treatment of human immunodeficiency virus-associated highly active antiretroviral therapy-resistant vacuolar myelopathy with intravenous immunoglobulin
by: Lidiia N Prakhova, et al.
Published: (2020-01-01)

Localized lipoatrophy and inadvertent subcutaneous administration of a COVID-19 vaccine
by: Ian F. Cook
Published: (2022-11-01)

Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty
by: Jin Li, et al.
Published: (2020-12-01)

"High Doses Intravenous Immunoglobulin versus Oral Cyclosporine in the Treatment of Severe Atopic Dermatitis "
by: "Mohammad Hassan Bemanian, et al.
Published: (2005-09-01)

INTRAVENOUS IMMUNOGLOBULINS: MECHANISMS OF THERAPEUTIC EFFECTS
by: V. A. Lazanovich, et al.
Published: (2014-08-01)

Analgesic Use Among Adults with a Trauma-Related Emergency Department Visit: A Retrospective Cohort Study from Alberta, Canada
by: Bill Sevcik, et al.
Published: (2023-06-01)